RavenQuest’s George Robinson Appointed Acting President & CEO of Bonify
January 16 2019 - 6:00AM
RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) –
(CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) announces George
Robinson, CEO, has been named interim President & CEO of Bonify
Medical Cannabis (BMC), Ltd. (“
Bonify”).
Bonify Chairman, Jeffery Dyck, stated that
“George Robinson’s knowledge and experience is superb when it comes
to cannabis production pursuant to Health Canada regulations. In
the wake of our recent product recall, Robinson and his team at
RavenQuest have been instrumental in preserving Bonify’s licenses
to cultivate, process and sell cannabis.”
“The appointment of Mr. Robinson as acting
President & CEO of Bonify is a natural evolution as our
organization takes corrective action to emerge as a stronger,
compliant and operationally sound licensee moving forward,” Dyck
continued.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer with
facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with Montreal’s McGill
University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant. The
Company focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson” Chief Executive Officer
For further information, please contact: Mathieu
McDonald, Corporate Communications – 604-484-1230
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to any future
performance of Bonify. The Company provides forward-looking
statements for the purpose of conveying information about current
expectations and plans relating to the future and readers are
cautioned that such statements may not be appropriate for other
purposes. By its nature, this information is subject to inherent
risks and uncertainties that may be general or specific and which
give rise to the possibility that expectations, forecasts,
predictions, projections or conclusions will not prove to be
accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. These risks
and uncertainties include but are not limited to those identified
and reported in the Company’s public filings under the Company’s
SEDAR profile at www.sedar.com. Although the Company has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Nov 2024 to Dec 2024
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Dec 2023 to Dec 2024